In recent years, a succession of large-scale studies indicated that SGLT2 inhibitors can also reduce the risk of cardiovascular outcomes in patients with CKD, particularly those with type 2 diabetes [10, 11]. This evidence concerns the gene SLC5A2 and chronic kidney disease.